Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma.
BACKGROUND: The transforming growth factor beta (TGF-beta) superfamily regulates cell growth in various cells. Previous studies have shown that altered expression of TGF-beta receptors, Smad2 and Smad4, as mediators of TGF-beta superfamily signaling, contributes to tumor progression in esophageal squamous cell carcinoma ( SCC). The expression of Smad6 and Smad7 as negative regulators was examined, to investigate the further effects of TGF-B superfamily signaling. MATERIALS AND METHODS: Immunohistochemical staining with anti-Smad6 and anti-Smad7 polyclonal antibodies was performed on surgical specimens obtained from 115 patients with esophageal SCC. RESULTS: The expression of Smad6 and Smad7 was inversely correlated with depth of invasion in the early stages (p = 0.0003 and p = 0.0173, respectively). Moreover, there was a significant correlation between the expression of Smad6 and Smad7, and poor survival rate (p = 0.0078 and p = 0.0207, respectively). CONCLUSION: Smad6 and Smad7 expression affects the progression of early lesions of esophageal SCC and indicates a poor prognosis.[1]References
- Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Osawa, H., Nakajima, M., Kato, H., Fukuchi, M., Kuwano, H. Anticancer Res. (2004) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
